HPGC Renmintongtai Pharmaceutical Corp (600829) - Net Assets

Latest as of March 2026: CN¥3.06 Billion CNY ≈ $448.28 Million USD

Based on the latest financial reports, HPGC Renmintongtai Pharmaceutical Corp (600829) has net assets worth CN¥3.06 Billion CNY (≈ $448.28 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.35 Billion ≈ $1.08 Billion USD) and total liabilities (CN¥4.29 Billion ≈ $627.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore HPGC Renmintongtai Pharmaceutical Corp (600829) total assets for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥3.06 Billion
% of Total Assets 41.66%
Annual Growth Rate 6.68%
5-Year Change 37.09%
10-Year Change 82.97%
Growth Volatility 18.14

HPGC Renmintongtai Pharmaceutical Corp - Net Assets Trend (1994–2025)

This chart illustrates how HPGC Renmintongtai Pharmaceutical Corp's net assets have evolved over time, based on quarterly financial data. Check HPGC Renmintongtai Pharmaceutical Corp (600829) tangible net worth to evaluate the tangible quality of the company's equity base.

Annual Net Assets for HPGC Renmintongtai Pharmaceutical Corp (1994–2025)

The table below shows the annual net assets of HPGC Renmintongtai Pharmaceutical Corp from 1994 to 2025. For live valuation and market cap data, see HPGC Renmintongtai Pharmaceutical Corp (600829) market capitalisation.

Year Net Assets Change
2025-12-31 CN¥3.01 Billion
≈ $441.19 Million		 +4.65%
2024-12-31 CN¥2.88 Billion
≈ $421.60 Million		 +4.72%
2023-12-31 CN¥2.75 Billion
≈ $402.61 Million		 +11.72%
2022-12-31 CN¥2.46 Billion
≈ $360.36 Million		 +11.98%
2021-12-31 CN¥2.20 Billion
≈ $321.82 Million		 +10.39%
2020-12-31 CN¥1.99 Billion
≈ $291.54 Million		 +7.85%
2019-12-31 CN¥1.85 Billion
≈ $270.31 Million		 +16.92%
2018-12-31 CN¥1.58 Billion
≈ $231.19 Million		 -1.99%
2017-12-31 CN¥1.61 Billion
≈ $235.89 Million		 -2.17%
2016-12-31 CN¥1.65 Billion
≈ $241.12 Million		 +15.77%
2015-12-31 CN¥1.42 Billion
≈ $208.27 Million		 -33.89%
2014-12-31 CN¥2.15 Billion
≈ $315.05 Million		 -4.62%
2013-12-31 CN¥2.26 Billion
≈ $330.33 Million		 -2.10%
2012-12-31 CN¥2.31 Billion
≈ $337.41 Million		 +19.12%
2011-12-31 CN¥1.94 Billion
≈ $283.25 Million		 +11.33%
2010-12-31 CN¥1.74 Billion
≈ $254.43 Million		 +4.96%
2009-12-31 CN¥1.66 Billion
≈ $242.41 Million		 +0.47%
2008-12-31 CN¥1.65 Billion
≈ $241.27 Million		 +17.29%
2007-12-31 CN¥1.41 Billion
≈ $205.71 Million		 +29.76%
2006-12-31 CN¥1.08 Billion
≈ $158.53 Million		 +21.97%
2005-12-31 CN¥888.23 Million
≈ $129.98 Million		 -14.62%
2004-12-31 CN¥1.04 Billion
≈ $152.24 Million		 +85.65%
2003-12-31 CN¥560.39 Million
≈ $82.00 Million		 +6.50%
2002-12-31 CN¥526.17 Million
≈ $77.00 Million		 +5.00%
2001-12-31 CN¥501.11 Million
≈ $73.33 Million		 +7.45%
2000-12-31 CN¥466.36 Million
≈ $68.24 Million		 +10.48%
1999-12-31 CN¥422.13 Million
≈ $61.77 Million		 -1.99%
1998-12-31 CN¥430.69 Million
≈ $63.02 Million		 +1.10%
1997-12-31 CN¥426.02 Million
≈ $62.34 Million		 +2.92%
1996-12-31 CN¥413.92 Million
≈ $60.57 Million		 +0.99%
1995-12-31 CN¥409.86 Million
≈ $59.98 Million		 +0.86%
1994-12-31 CN¥406.37 Million
≈ $59.46 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to HPGC Renmintongtai Pharmaceutical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 8672.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CN¥2.33 Billion 77.30%
Other Components CN¥684.44 Million 22.70%
Total Equity CN¥3.02 Billion 100.00%

HPGC Renmintongtai Pharmaceutical Corp Competitors by Market Cap

The table below lists competitors of HPGC Renmintongtai Pharmaceutical Corp ranked by their market capitalization.

Company Market Cap
Bangkok Chain Hospital Public Company Limited
BK:BCH
 $878.33 Million
Janux Therapeutics Inc
NASDAQ:JANX
 $878.78 Million
Hunan Jingfeng Pharmaceutical
SHE:000908
 $879.28 Million
IPERIONX LTD SP.ADR/10
F:30Z0
 $879.39 Million
AirAsia X Bhd
KLSE:5238
 $877.55 Million
KSB SE & Co. KGaA
F:KSB3
 $877.50 Million
UNITIL Corporation
NYSE:UTL
 $877.29 Million
Yuanta Futures Co Ltd
TWO:6023
 $877.05 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in HPGC Renmintongtai Pharmaceutical Corp's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 2,881,186,525 to 3,015,026,455, a change of 133,839,930 (4.6%).
  • Net income of 133,839,930 contributed positively to equity growth.
  • Dividend payments of 20,077,490 reduced retained earnings.
  • Other comprehensive income decreased equity by 104,547,325.
  • Other factors increased equity by 124,624,815.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥133.84 Million +4.44%
Dividends Paid CN¥20.08 Million -0.67%
Other Comprehensive Income CN¥-104.55 Million -3.47%
Other Changes CN¥124.62 Million +4.13%
Total Change CN¥- 4.65%

Book Value vs Market Value Analysis

This analysis compares HPGC Renmintongtai Pharmaceutical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.99x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 14.82x to 1.99x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1994-12-31 CN¥0.70 CN¥10.35 x
1995-12-31 CN¥0.70 CN¥10.35 x
1996-12-31 CN¥0.71 CN¥10.35 x
1997-12-31 CN¥0.73 CN¥10.35 x
1998-12-31 CN¥0.74 CN¥10.35 x
1999-12-31 CN¥0.73 CN¥10.35 x
2000-12-31 CN¥0.80 CN¥10.35 x
2001-12-31 CN¥0.86 CN¥10.35 x
2002-12-31 CN¥0.91 CN¥10.35 x
2003-12-31 CN¥0.97 CN¥10.35 x
2004-12-31 CN¥1.03 CN¥10.35 x
2005-12-31 CN¥1.31 CN¥10.35 x
2006-12-31 CN¥1.65 CN¥10.35 x
2007-12-31 CN¥2.17 CN¥10.35 x
2008-12-31 CN¥2.56 CN¥10.35 x
2009-12-31 CN¥2.57 CN¥10.35 x
2010-12-31 CN¥2.75 CN¥10.35 x
2011-12-31 CN¥3.11 CN¥10.35 x
2012-12-31 CN¥3.73 CN¥10.35 x
2013-12-31 CN¥3.73 CN¥10.35 x
2014-12-31 CN¥3.61 CN¥10.35 x
2015-12-31 CN¥2.45 CN¥10.35 x
2016-12-31 CN¥2.84 CN¥10.35 x
2017-12-31 CN¥2.78 CN¥10.35 x
2018-12-31 CN¥2.70 CN¥10.35 x
2019-12-31 CN¥3.19 CN¥10.35 x
2020-12-31 CN¥3.43 CN¥10.35 x
2021-12-31 CN¥3.79 CN¥10.35 x
2022-12-31 CN¥4.25 CN¥10.35 x
2023-12-31 CN¥4.74 CN¥10.35 x
2024-12-31 CN¥4.97 CN¥10.35 x
2025-12-31 CN¥5.20 CN¥10.35 x

Capital Efficiency Dashboard

This dashboard shows how efficiently HPGC Renmintongtai Pharmaceutical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 4.44%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 1.29%
  • • Asset Turnover: 1.45x
  • • Equity Multiplier: 2.38x
  • Recent ROE (4.44%) is below the historical average (10.62%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1994 7.72% 11.31% 0.46x 1.50x CN¥-9.23 Million
1995 3.11% 4.80% 0.42x 1.55x CN¥-28.14 Million
1996 2.32% 3.63% 0.41x 1.56x CN¥-31.79 Million
1997 1.98% 2.73% 0.46x 1.57x CN¥-34.18 Million
1998 0.18% 0.22% 0.52x 1.56x CN¥-42.29 Million
1999 0.55% 0.60% 0.54x 1.68x CN¥-39.89 Million
2000 13.20% 11.90% 0.52x 2.15x CN¥14.91 Million
2001 8.82% 8.48% 0.54x 1.92x CN¥-5.90 Million
2002 1.92% 2.01% 0.54x 1.77x CN¥-42.51 Million
2003 3.17% 3.48% 0.48x 1.92x CN¥-38.25 Million
2004 4.45% 4.15% 0.34x 3.12x CN¥-33.28 Million
2005 19.11% 8.20% 0.89x 2.62x CN¥69.17 Million
2006 22.84% 10.57% 0.92x 2.34x CN¥122.68 Million
2007 21.32% 11.82% 0.85x 2.13x CN¥142.37 Million
2008 18.11% 10.38% 0.89x 1.96x CN¥120.56 Million
2009 18.69% 10.57% 0.92x 1.91x CN¥129.65 Million
2010 20.97% 11.11% 0.90x 2.09x CN¥174.61 Million
2011 22.13% 11.05% 0.94x 2.13x CN¥218.47 Million
2012 16.81% 8.95% 1.00x 1.87x CN¥147.45 Million
2013 0.30% 0.20% 0.86x 1.70x CN¥-210.68 Million
2014 8.96% 2.08% 2.75x 1.57x CN¥-21.87 Million
2015 9.76% 1.56% 2.10x 2.97x CN¥-3.41 Million
2016 13.63% 2.49% 1.87x 2.92x CN¥59.73 Million
2017 15.77% 3.17% 1.65x 3.00x CN¥92.99 Million
2018 16.32% 3.65% 1.60x 2.79x CN¥99.87 Million
2019 14.47% 3.20% 1.51x 3.00x CN¥82.61 Million
2020 7.29% 1.81% 1.34x 3.01x CN¥-53.99 Million
2021 12.60% 2.98% 1.38x 3.07x CN¥57.27 Million
2022 10.74% 2.74% 1.37x 2.87x CN¥18.11 Million
2023 10.62% 2.81% 1.40x 2.70x CN¥17.02 Million
2024 7.40% 2.12% 1.40x 2.49x CN¥-74.85 Million
2025 4.44% 1.29% 1.45x 2.38x CN¥-167.66 Million

Industry Comparison

This section compares HPGC Renmintongtai Pharmaceutical Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,133,881,544
  • Average return on equity (ROE) among peers: 2.68%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
HPGC Renmintongtai Pharmaceutical Corp (600829) CN¥3.06 Billion 7.72% 1.40x $878.26 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $868.76 Million 4.89% 3.05x $639.13 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $775.01 Million 2.45% 0.87x $378.07 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $5.07 Billion
Livzon Pharmaceutical Group Inc (000513) $662.32 Million 12.10% 0.68x $2.59 Billion
Wedge Industrial Co Ltd (000534) $692.08 Million 2.78% 1.05x $1.97 Billion
Yunnan Baiyao Group Co Ltd (000538) $3.19 Billion 14.61% 0.55x $13.23 Billion
Hainan Haiyao Co Ltd (000566) $1.49 Billion 5.19% 0.85x $1.11 Billion
Tus Pharmaceutical Group Co Ltd (000590) $231.22 Million -38.13% 1.23x $302.41 Million
Northeast Pharmaceutical Group Co Ltd (000597) $1.75 Billion 0.46% 2.42x $956.43 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.35 Billion 7.34% 0.44x $3.16 Billion

About HPGC Renmintongtai Pharmaceutical Corp

SHG:600829 China Drug Manufacturers - Specialty & Generic
Market Cap
$878.26 Million
CN¥6.00 Billion CNY
Market Cap Rank
#9472 Global
#2391 in China
Share Price
CN¥10.35
Change (1 day)
+9.99%
52-Week Range
CN¥7.76 - CN¥17.72
All Time High
CN¥17.72
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese and Western patent medicines, Chinese herbal medicines and slices, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices, and health products, as well as tonic health, daily necessities, and cosm… Read more